{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:51:44Z","timestamp":1786369904926,"version":"build-2736575974"},"reference-count":19,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Atopic dermatitis (AD) is characterized by substantial clinical heterogeneity. Global severity is typically assessed using scores such as the POEM; however, lesion localization \u2014\u2013 particularly on the face \u2013\u2014 may generate psychosocial consequences partly independent of overall disease severity. This cross-sectional observational study (VISEABLE) included 1,400 French adults with physician-confirmed AD. Severity was measured using the POEM (Clear\/Almost Clear: 0\u20137 vs. Moderate\u2013severe: \u22658) and facial involvement using the BoFA (0\u2013109; threshold=36, population median). Six phenotypes were defined through a 2\u00d73 combination. The POEM and BoFA correlation was moderate (r=0.365; \u03c1=0.389; p&lt;0.001). Phenotype Ph3 (Clear\/Almost Clear POEM \/ Severe facial involvement, n=58) exhibited stigmatization scores (PUSH-d=21.93) and life trajectory impact (DLLIM=14.76) not significantly different from Ph4 (Moderate\u2013severe POEM \/ No facial involvement, n=527; p&gt;0.25 for all comparisons). In multiple regression analysis restricted to patients with facial involvement, BoFA was the dominant independent predictor of stigmatization (\u03b2=11.44, p&lt;0.001; partial R\u00b2=46.2 %; overall R\u00b2=0.532), superseding POEM (p=0.076, ns; partial R\u00b2=0.6%). Mild eczema with severe facial involvement generates a psychosocial burden comparable to that of moderate-to-severe eczema without facial involvement. Systematic BoFA assessment is essential in all patients with AD.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2026-0622","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:15:05Z","timestamp":1786367705000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Phenotyping of Atopic Dermatitis Using Combined Global Severity (POEM) and Facial Burden (BoFA): A French Population-based Observational Study"],"prefix":"10.2340","volume":"106","author":[{"given":"Jean Michel","family":"AMICI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Sylvie","family":"Doutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-6750","authenticated-orcid":false,"given":"Bruno","family":"Halioua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Bourne Chastel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Merhand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5142-2479","authenticated-orcid":false,"given":"Charles","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Staumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"165189","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol 2022; 36: 1409\u20131431.","DOI":"10.1111\/jdv.18345"},{"key":"165190","doi-asserted-by":"crossref","unstructured":"Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984\u2013991.","DOI":"10.1038\/jid.2014.530"},{"key":"165191","unstructured":"Grosperrin A. Depression and anxiety in visible skin diseases: a systematic review of the literature [thesis]. Universit\u00e9 de Lorraine; 2024."},{"key":"165192","doi-asserted-by":"crossref","unstructured":"Seneschal J, Halioua B, Tan J, Gu C, Luger T, Dodiuk-Gad R, et al. Suicidal ideation in patients with atopic dermatitis: a case-control study on 23,191 adults. J Eur Acad Dermatol Venereol 2026; 40: e375\u2013e378.","DOI":"10.1111\/jdv.70138"},{"key":"165193","doi-asserted-by":"crossref","unstructured":"Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99\u2013106.","DOI":"10.1111\/j.1398-9995.2011.02719.x"},{"key":"165194","doi-asserted-by":"crossref","unstructured":"Richard MA, Saint Aroman M, Baissac C, Merhand S, Aubert R, Audouze A, et al. Burden of visible [face and hands] skin diseases: results from a large international survey. Ann Dermatol Venereol 2023; 150: 95\u2013100.","DOI":"10.1016\/j.annder.2022.11.008"},{"key":"165195","doi-asserted-by":"crossref","unstructured":"Doutre MS, Godard D, Benani M, Taieb C. Cr\u00e9ation et validation d\u2019un outil d\u2019\u00e9valuation du handicap li\u00e9 \u00e0 l\u2019atteinte du visage de la scl\u00e9rodermie syst\u00e9mique. Ann Dermatol Venereol 2020; 147: 595\u2013601.","DOI":"10.1016\/j.annder.2020.04.023"},{"key":"165196","doi-asserted-by":"crossref","unstructured":"Chovatiya R, Lei D, Ahmed A, Chavda R, Gabriel S, Silverberg JI. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol 2021; 127: 83\u201390.","DOI":"10.1016\/j.anai.2021.03.019"},{"key":"165197","doi-asserted-by":"crossref","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol 2004; 140: 1513\u20131519.","DOI":"10.1001\/archderm.140.12.1513"},{"key":"165198","doi-asserted-by":"crossref","unstructured":"Ezzedine K, Shourick J, Bergqvist C, Misery L, Chuberre B, Kerob D, et al. Patient Unique Stigmatization Holistic tool in dermatology (PUSH-D): development and validation of a dermatology-specific stigmatization assessment tool. J Eur Acad Dermatol Venereol 2023; 37: 443\u2013450.","DOI":"10.1111\/jdv.18641"},{"key":"165199","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Skayem C, Flavigny AD, Le Floc\u2019h C, Merhand S, Begolka WS, et al. Chronic skin diseases and life trajectories: development and validation of \u201cDermatology Long-Term Life Impact Measure\u201d. J Am Acad Dermatol 2026; 94: 81\u201387.","DOI":"10.1016\/j.jaad.2025.08.042"},{"key":"165200","doi-asserted-by":"crossref","unstructured":"Halioua B, Skayem C, Merhand S, Demessant-Flavigny AL, Ben Hayoun Y, Sampogna F, et al. Validation of the dermatological mental load questionnaire in patients with atopic dermatitis. Clin Exp Dermatol 2025; 50: 2276\u20132278.","DOI":"10.1093\/ced\/llaf290"},{"key":"165201","unstructured":"Dancey CP, Reidy J. Statistics Without Maths for Psychology: Using SPSS for Windows. Prentice Hall\/Pearson Education; 2004."},{"key":"165202","doi-asserted-by":"crossref","unstructured":"Germain N, Augustin M, Fran\u00e7ois C, Legau K, Bogoeva N, Desroches M, et al. Stigma in visible skin diseases - a literature review and development of a conceptual model. J Eur Acad Dermatol Venereol 2021; 35: 1493\u20131504.","DOI":"10.1111\/jdv.17110"},{"key":"165203","doi-asserted-by":"crossref","unstructured":"Heratizadeh A, Haufe E, St\u00f6lzl D, Abraham S, Heinrich L, Kleinheinz A, et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol 2020; 34: 1263\u20131272.","DOI":"10.1111\/jdv.16078"},{"key":"165204","doi-asserted-by":"crossref","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287\u20132303.","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"165205","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 2020; 156: 411\u2013420.","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"165206","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 863\u2013873.","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"165207","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437\u2013449.","DOI":"10.1111\/bjd.19574"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46679\/55074","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46679\/55075","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46679\/55076","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46679\/55074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:15:10Z","timestamp":1786367710000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":19,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0622","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,10]]}}}